



## News Release

### **Suven Life Sciences secures Two Product Patents in all Russian countries (Eurasia Region)**

Hyderabad, India (March 24, 2008) – Suven Life Sciences Ltd (Suven) announces today that two product patents were granted in Eurasia (009193 and 009367) for two of their New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid until 2023. The patents are valid in all contracting countries like Armenia, Azerbaijan, Belarus, Kyrgyzstan, Kazakhstan, Moldova, Russia, Tajikistan and Turkmenistan.

These granted patents are exclusive intellectual property of Suven and are achieved through the exclusive internal discovery research efforts. Products out of these inventions which are in pre-clinical development may be out-licensed at the stage of clinical Phase-I or Phase-II stage.

**“We are very pleased by the issuance of these patents to Suven for our drug candidates that are being developed for CNS disorders which targets an \$18 billion potential market opportunity globally “says Venkat Jasti, CEO of Suven.**

The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neuro-degenerative disorders like Attention deficient hyperactivity, Alzheimer’s, Parkinson, Schizophrenia and Huntington’s.

Suven Life Sciences is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are **first in class or best in class** therapies through the use of GPCR targets. The company has six internally-discovered therapeutic drug candidates currently in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression, Huntington’s disease, Parkinson’s’ disease and obesity in addition to developmental candidates in Alzheimer’s disease and Schizophrenia.

#### **Risk Statement:**

***Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;***